The rewarding properties of opioids are essential driving force for compulsive drug-seeking and drug-taking behaviors in the development of opioid-mediated drug addiction. Prior drug use enhances sensitivity to the rewarding effects of subsequently used drugs, increasing vulnerability to relapse. The molecular mechanisms underlying this reward sensitization are still unclear. We report here that morphine that induced reward sensitization, as demonstrated by reinstatement of the behavior of conditioned place preference (CPP) with sub-threshold priming morphine, epigenetically upregulated the output activity of Ngf encoding the nerve growth factor (NGF) by increasing histone H4 acetylation in the rat central nucleus of the amygdala (CeA). NGF locally infused into the CeA mimicked the morphine effect in inducing new functional delta-opioid receptor (DOR) that was required for the reward sensitization, and morphineinduced reward sensitization was inhibited by blocking NGF receptor signaling in the CeA. Histone deacetylase inhibitors that increased the acetylation level at the Ngf promoter and NGF expression in the CeA also induced reward sensitization in a CeA NGF signaling-and DOR-dependent manner. Furthermore, CeA-applied NGF substituted prior morphine to induce reward sensitization in naive rats and also substituted priming morphine to reinstate the CPP induced by prior morphine. Thus, epigenetic upregulation of NGF activity in the CeA may promote the behavior of opioid reward and increase the sensitivity to the rewarding effect of subsequent opioids, a potentially important mechanism in drug addiction.
INTRODUCTION
Drug addiction is a chronically relapsing neuropsychiatric disorder characterized by compulsive drug taking, which is driven by the rewarding effect of drugs of abuse, including opioids, and by a negative emotional state of withdrawal syndrome (Hyman et al, 2006; Koob, 2008) . Prior use of abused drugs can augment the sensitivity to the effects of subsequently administered drugs, a likely cause for relapse (Koob et al, 2009 ), but the underlying neurobiological mechanisms remain largely unclear. Among drug rewardrelated brain areas, the central nucleus of the amygdala (CeA) has emerged recently as an important brain region that mediates stimulus-reward learning and drug-seeking behaviors in drug addiction (Baxter and Murray, 2002; Gottfried et al, 2003; Le Merrer et al, 2009) . Abused drugs induce long-lasting, multifaceted neural maladaptations in brain circuits, particularly glutamate synapses, which have a central role in learning and adaptive responses to repeatedly administered drugs of abuse (Carlezon and Nestler, 2002; Jones and Bonci, 2005; Luscher and Malenka, 2011; Russo et al, 2010; Siggins et al, 2003) .
Opioids effects are mediated by three types of opioid receptors: mu (MOR), delta (DOR), and kappa (Le Merrer et al, 2009; Pan, 1998; Waldhoer et al, 2004) . The rewarding effect of opioids is primarily mediated by MOR (Contet et al, 2004; Matthes et al, 1996) , but the role of DOR in opioid reward and drug addiction is still largely unknown (Le Merrer et al, 2009) . Recent studies show that DOR in central neurons normally lacks function because of its constitutively intracellular localization, but becomes functional through membrane trafficking under various pathological conditions including chronic opioid exposure (Bie et al, 2009b (Bie et al, , 2010 Cahill et al, 2007; Commons, 2003; Hack et al, 2005; Ma et al, 2006) . This indicates that DOR may have a critical role in adaptive responses and neuronal plasticity underlying the mechanisms for chronic opioid-associated diseases such as drug addiction and drug sensitization in relapse.
The neurotrophin brain-derived neurotrophic factor (BDNF) has been demonstrated to promote the behavior of cocaine addiction (Graham et al, 2007; Lu et al, 2004) . In contrast, the role of nerve growth factor (NGF) in drug addiction is still unclear. For example, although NGF was epigenetically downregulated in the serum of alcohol-dependent patients after withdrawal (Heberlein et al, 2011) , infusion of NGF into the ventral tegmental area failed to change cocaineseeking behavior, which was enhanced by similar infusion of BDNF (Lu et al, 2004) . We have shown recently that NGF can induce new functional DOR in CeA neurons, indicating a potential NGF role in CeA-related behavior of opioid addiction (Bie et al, 2010) . In this study, we examined opioid regulation of Ngf gene activity in CeA neurons and roles of CeA NGF in opioid-induced behaviors of reward sensitization.
MATERIALS AND METHODS

Animals and Microinjection
All procedures involving the use of animals conformed to the guidelines by the Institutional Animal Care and Use Committee of the University of Texas MD Anderson Cancer Center. Male Wistar rats, weighing 200-250 g, were used. General methods for CeA-specific drug infusion have been described in details in our previous studies (Bie et al, 2009a; Zhu et al, 2007) . A 26-gauge single guide cannula was implanted, aiming at the CeA (AP: À2.3 mm; L: ±4.0 mm; V: À8.0 mm) on both sides of the brain before conditioning treatment. Drugs were infused bilaterally in a volume of 0.5 ml into the CeA on each side through a 33-gauge single injector with an infusion pump at a rate of 0.1 ml/min. The injection sites for the CeA were histologically verified afterward by injecting 0.5 ml of a blue dye, as shown before (Bie et al, 2009a) . For CeA pre-treatment, Trichostatin A (TsA, 2.5 mg) was infused into the CeA 4 h before conditioning with priming morphine. K252a (24 ng) was infused into the CeA 30 min before the posttest or conditioning with priming morphine, or was co-infused with TsA. Naltrindole (NTD, 0.45 mg) was infused once 30 min before the conditioned place preference (CPP) test 1 day after CPP establishment or 30 min before the CPP test for CPP reinstatement with priming morphine. DMSO was used as vehicle for these drugs. For NGF substitution of morphine conditioning, NGF (0.05 mg) was infused into the CeA 4 h before priming morphine. For NGF-reinstated CPP, the rat was conditioned (confined to the previous morphine-paired chamber) three times at 15 min, 2 h, and 4 h after a single bilateral CeA infusion of NGF at the same dose, followed by saline conditioning on the following day. NGF-reinstated CPP was examined on the 3 days (D1-D3) following the day of saline conditioning.
Conditioned Place Preference
General methods of CPP have been described in our previous reports (Bie et al, 2009b; Zhu et al, 2007) . With a standard three-chamber rat CPP apparatus (MED Associates, St Albans, VT), the conditioning procedure consisted of four phases. Phase 1 (habituation, days 1-2): after an intraperitoneal (i.p.) saline injection, a rat was allowed to move freely between the chambers for 30 min each day. Phase 2 (pretest, day 3): after an i.p. saline injection, a CPP test (pretest) was conducted in a 30-min test period, which determines the baseline chamber preference or chamber bias. Phase 3 (morphine conditioning, days 4-11): the rat in the morphine group was injected with morphine (10 mg/kg, i.p.) or saline and was immediately confined in a chamber for 20 min on alternate days (four morphine and four saline sessions). Conditioning with morphine was paired with the non-preferred chamber of two conditioning apparatuses with different amount of equipment bias to access equipment bias-independent CPP measurements. CPP also can be consistently induced by morphine paired with the preferred chamber (Zhu et al, 2007) . Rats in the saline group were similarly conditioned with saline only (eight saline sessions). Phase 4 (posttest, day 12): after an i.p. saline injection, a CPP test (posttest) was performed for 30 min on the conditioned rat and CPP behavior was determined by comparing the pretest and posttest on the same rat. The preference data were expressed as the percentage of time in the morphinepaired chamber over the total time in both test chambers.
CPP Extinction and Reinstatement
For CPP extinction, rats were injected with saline and then confined to the previous morphine-paired chamber for 20 min daily for 10 days. CPP extinction was confirmed by a CPP test. To reinstate the CPP, the rat was injected with morphine (1 mg/kg, i.p.) and then confined to the previous morphine-paired chamber for 20 min, and on the following day, the rat was injected with saline and confined in the other chamber for 20 min. A day later, a CPP test was performed to confirm the CPP reinstatement. The effect of a CeA-infused drug was examined by a CPP test 1 day after posttest or after CPP reinstatement. For NGF-reinstated CPP, bilateral CeA infusion of NGF (0.05 mg/0.5 ml each side) substituted priming morphine for conditioning at 15 min, 2 h, and 4 h after NGF infusion, followed by CPP tests over 3 days.
Chromatin Immunoprecipitation Assay (ChIP)
The ChIP assay was performed as we previously described (Wang et al, 2007; Zhang et al, 2011) . CeA tissues were collected from rats at different behavioral stages of CPP immediately after the posttest for the stage of CPP establishment, after extinction training and confirming CPP test for extinction, and after test of reinstated CPP for reinstatement. Tissues were cross-linked with 2% formaldehyde. Chromatin was solubilized and sonicated to produce fragments of approximately 400 bp. One-third of the pre-immunoprecipitation (IP) lysate was used to determine the input of DNA. The input-level control was processed with the eluted IP. The polyclonal antibody against acetylated H4 at K5, K8, K12, and K16 (Upstate Biotechnology) was used at 1 : 100 dilution. Immunocomplexes were recovered by adding 30 ml of the salmon sperm DNA/protein A agarose beads. After reversal of the cross-linking between histones and DNA, DNA fragments were purified and chromatin from crosslinked CeA tissues was sonicated and IP with the antiacetylated H4 antibody. DNA co-IP with acetylated histone H4 and input DNA were purified by reverse cross-linking, followed by phenol-chloroform extraction. DNA was then quantified in a NanoDrop spectrophotometer (NanoDrop Technologies). Global histone H4 acetylation levels were expressed as the ratio of the amount of DNA associated with the acetylated chromatin to input DNA. The entire protocol was repeated four times to obtain the means and SEM.
PCR
Real-time PCR was performed using the ABI SYBR Green PCR protocol (Applied Biosystems) as described before (Ma et al, 2006) . Primers were designed to amplify approximately 200-bp fragments within the Ngf transcriptional control region. Gapdh was used as the internal control. For ChIP assay to detect H4 acetylation across the Ngf promoter region, the primers sets were:
. Amplifications were run in triplicate and the changes on histone H4 acetylation were calculated by the DDCT method. The amount of DNA recovered in the IP was expressed as the ratio of input DNA with the equation:
. Reverse transcription and real-time PCRs were performed in triplicate with Ngf exon primers (5
Synaptosome Preparations and Western Blot
Detailed methods of western assays and synaptosome preparations have been reported previously (Bie et al, 2010) . CeA tissues were gently homogenized in ice-cold 0.32 M sucrose buffer and centrifuged at 1000 Â g (4 1C).
The supernatant was collected and centrifuged at 10 000 Â g (4 1C), and the synaptosomal pellet was re-suspended in a lysis buffer (0.1% Triton X-100, 150 mM NaCl, 25 mM KCl, 10 mM Tris-HCl, pH 7.4, with protease inhibitors). For total protein preparations, CeA tissues from saline-and morphine-conditioned rats were homogenized in the lysis buffer, the lysates were centrifuged at 14 000 r.p.m., and the supernatant was used for SDS-PAGE. Protein concentrations were determined by the Bio-Rad (Hercules, CA) protein assay kit. Proteins were separated and electrotransferred onto nitrocellulose membrane. The amount of protein loaded in each lane was 20 mg. Samples were incubated overnight at 4 1C with a primary antibody for NGF (1 : 1000, Sigma), DOR (1 : 250, Santa Cruz Biotechnology), b-actin (1 : 200, Santa Cruz Biotechnology), or synaptophysin (1 : 2500, Millipore). For immunobloting, 15% SDS-polyacrylamide gel was used for NGF and 10% gel for DOR with composition including 29 : 1 40% acrylamide, sodium dodecyl sulfate, H 2 O, N,N,N 0 ,N 0 -tetramethylethylenediamine, and ammonium persulfate. After washes, the blots were incubated with horseradish peroxidase-conjugated secondary antibody (1 : 10 000) (Amersham, Arlington Heights, IL) for 1 h. Immunoreactive proteins were detected by the enhanced chemiluminescence advance kit (Amersham). The intensity of bands was digitally captured and quantitatively analyzed with the software Kodak 1D (Eastman, Kodak, Rochester, NY). The immunoreactivity of target proteins was normalized to that of b-actin for total protein, or to the specific synaptic terminal marker synaptophysin for synaptosomal proteins.
Slice Preparations and Whole-Cell Recording
General recording methods are the same as in previous studies (Bie et al, 2009b (Bie et al, , 2010 . Visualized whole-cell voltage-clamp recordings were obtained from neurons in the medial part of the CeA in a slice with a glass pipette (resistance 2-4 MO) containing (in mM): K-gluconate, 126; NaCl, 10; MgCl 2 , 1; EGTA, 11; HEPES, 10; ATP, 2; GTP, 0.25; pH adjusted to 7.3 with KOH; osmolarity 280-290 mOsm/l. Electrical stimuli of constant current (0.25 ms, 0.04-0.2 mA) were used to evoke glutamate-mediated excitatory postsynaptic currents (EPSCs) in GABA A receptor antagonist bicuculline (30 mM). Recordings in slices from all rats were made in a morphine-free solution 1-3 h after making the slice preparation. Drugs were applied through the bath solution. 
Statistics and Materials
RESULTS
As we reported before (Bie et al, 2009b; Zhu et al, 2007) , conditioning with morphine (10 mg/kg, i.p.), but not saline, in rats consistently induced the CPP behavior (Figure 1a) , a common behavioral measure of drug reward in rodents (Tzschentke, 2007) . The established CPP behavior was extinguished after daily conditioning with saline only for 10 days (n ¼ 15 rats) and the CPP was reinstated by conditioning with a single, sub-threshold dose of priming morphine (1 mg/kg, i.p., n ¼ 10), which was ineffective in salineconditioned naive rats (n ¼ 7, Figure 1b ). This suggests that pre-exposure to morphine increases the sensitivity to the rewarding effect of subsequent morphine.
Given our recent finding of opioid-induced increase in NGF activity in brainstem pain-modulating neurons (Bie et al, 2010) , we determined molecular mechanisms underlying the morphine-induced sensitivity increase, focusing on epigenetic regulation of CeA NGF expression and its functions. We found that the global level of histone acetylation was significantly increased in CeA lysates from rats with established CPP (Figure 1c) . After CPP extinction, the global histone acetylation returned to pre-CPP levels, and increased again following CPP reinstatement. Using the CHIP assay (Zhang et al, 2011 ), we found that the level of histone H4 acetylation across the Ngf promoter region displayed similar CPP-correlated changes to those of global acetylation levels, increasing on CPP establishment and reinstatement (Figure 1d ). The priming morphine failed to change the level of either global acetylation or acetylation in the Ngf promoter region in saline-conditioned control rats. The acetylation level of histone H4 at the Gapdh promoter region was not significantly altered regardless of opioid treatments or CPP conditions (Figure 1e ). Thus, it appears that morphine-induced CPP is associated with epigenetic activation of Ngf transcription through histone hyperacetylation. As expected, we found that both the NGF mRNA and NGF protein levels were also significantly increased in CeA tissues from rats with CPP establishment and CPP reinstatement, but not after CPP extinction (Figures 1f-h) . Additionally, CeA neurons displayed increased expression of NGF detected immunocytochemically in rats with morphine-induced CPP behavior (Supplementary Figure S1) .
In CeA slices, the selective DOR agonist DPDPE (1 mM), having no effect in CeA neurons from saline-conditioned rats, significantly inhibited the amplitude of evoked glutamatergic EPSCs in 13 of 19 (68%) cells generally surveyed in CeA neurons from morphine-conditioned rats displaying established CPP. This appearance of functional DOR was temporally correlated to CPP, present only with CPP established or reinstated by priming morphine (Figures 2a  and b) . The priming morphine itself was unable to induce functional DOR in naive rats. To determine a causal role of the DOR in CPP behavior, we then conducted behavioral experiments in rats with an implanted CeA cannula. Bilateral infusion of the selective DOR antagonist NTD (0.45 mg in 0.5 ml each side) into the CeA, which blocks DOR function in vivo (Bie et al, 2009a; Cornish et al, 2005; Schmidt et al, 2002; Ward and Roberts, 2007) , had no effect on baseline preference behavior in saline-conditioned naive rats, indicating the absence of functional DOR or lack of tonic DOR effect under control conditions. However, in morphine-conditioned rats, NTD significantly inhibited the CPP 1 day after CPP establishment ( Figure 2c ) when the CPP persisted otherwise (Bie et al, 2009a; Zhu et al, 2007) . CeA-applied NTD also significantly attenuated priming morphine-reinstated CPP ( Figure 2d ).
As morphine epigenetically upregulated Ngf expression and induced new DOR in CeA neurons, we next determined whether the NGF upregulation and NGF signaling was involved in morphine induction of DOR and reward sensitization. In contrast to its ineffectiveness in control slices, the DOR agonist DEDPE (1 mM) significantly inhibited EPSCs in CeA neurons in naive slices incubated with NGF (100 ng/ml) in vitro for 4 h (n ¼ 9 out of 12 (75%) cells surveyed, Figure 3a) . The NGF treatment also induced functional DOR (n ¼ 6 out of 8 (75%) cells surveyed) in CeA slices from morphine-treated rats with the CPP extinction (Figure 3b ). In addition, in CeA slices from morphine-treated rats with either established CPP or reinstated CPP, the DOR agonist was no longer effective after incubating the slices for 4 h in vitro with K252a (0.2 mM), an inhibitor of the NGF receptor tyrosine receptor kinase (Trk) (Figures 3c and d) . Furthermore, bilateral CeA infusion of K252a (24 ng) inhibited morphine-induced CPP (n ¼ 6 rats) whereas it did not alter the preference behavior in saline-conditioned rats (n ¼ 4 rats, Figure 3e ). CeA-infused K252a also attenuated priming morphine-reinstated CPP (n ¼ 6 rats, Figure 3f) .
Next, we determined whether the epigenetic upregulation of CeA NGF was essential for the reward sensitization. We induced histone hyperacetylation with TsA, a commonly used histone deacetylase inhibitor that increases histone acetylation non-selectively (Finnin et al, 1999; Zhang et al, 2011) . Mimicking the effect of morphine conditioning Figure 1 Morphine epigenetically activates the Ngf gene and the expression of nerve growth factor (NGF) in the central nucleus of the amygdala (CeA) of rats with increased sensitivity to morphine reward. (a) Behaviors of conditioned place preference (CPP), expressed as the time spent in the conditioning chamber before (pretest) and after conditioning (posttest), in saline-conditioned rats (one-way ANOVA (same below): F (1,12) ¼ 0.009, n ¼ 13) and in morphine-conditioned rats (F (1,25) ¼ 58.47, n ¼ 26). (b) CPP behaviors in morphine-conditioned rats after CPP establishment (F (1,9) ¼ 26.59), extinction (F (1,9) ¼ 52.98), and reinstatement (F (1,9) ¼ 42.06) by a single priming dose of morphine (1 mg/kg, i.p.), and in saline-conditioned naive rats either as control or after conditioning with the priming morphine (F (1,6) ¼ 1.08). N ¼ 7-15 rats in each group. (c) Normalized levels of global acetylated histone H4, expressed as the ratio of DNA associated with the acetylated H4 to input DNA, in CeA tissues from saline-conditioned naive rats, from morphine-conditioned rats with CPP established, extinguished and reinstated, and from saline-conditioned naive rats after conditioning with priming morphine. (d, e) Levels of H4 acetylation across the Ngf promoter region (d) and across the Gapdh promoter region (e) in similar groups of rats to those in (a). N ¼ 5-7 rats for each group. (f) Changes in NGF mRNA levels in CeA tissues from similar groups of morphine-conditioned rats at the three indicated CPP stages and of saline-conditioned rats without or after conditioning with priming morphine. N ¼ 5 rats for each group. (g, h) Representative western blots (g) and group data of NGF protein levels normalized to b-actin (h) in CeA tissues from similar rat groups as indicated. N ¼ 5 rats for each group. Summarized data are mean±SEM. *po0.05, **po0.01. Establ., establishment; Reinst., reinstatement.
Nerve growth factor and reward sensitization B Bie et al (Figure 1b) , pre-treatment of naive rats by CeA infusion of TsA (2.5 mg) increased the sensitivity to opioid reward, as priming morphine (1 mg/kg) induced CPP behavior in TsAtreated, opioid-naive rats (n ¼ 7), but not in vehicle-treated rats (n ¼ 5, Figure 4a ). As expected, the CeA pre-treatment with TsA significantly increased the levels of global histone H4 acetylation, H4 acetylation on the Ngf promoter, and NGF mRNA in the CeA from naive rats with priming morphine-induced CPP (Figure 4b) . Additionally, expression of CeA NGF protein and synaptosomal DOR protein were also increased in the CeA from these rats (Figures 4c-e) . As TsA-induced hyperacetylation is global, we then determined whether the TsA induction of reward sensitization was dependent on NGF signaling in the CeA. We found that, after bilateral CeA infusion of the Trk receptor antagonist K252a (24 ng), priming morphine could no longer induce CPP in the TsA pre-treated rats (Figure 4f) , and so was the case after CeA infusion of DOR antagonist NTD (0.45 mg, Figure 4g ). In addition, blocking Trk also inhibited the elevated level of CeA synaptosomal DOR protein induced by TsA pre-treatment and priming morphine (Figure 4h) .
To further support such a role of CeA NGF in reward sensitization, we determined whether exogenously applied NGF by itself in the CeA was sufficient to induce reward sensitization. In naive rats pre-treated (4 h before) with bilateral CeA infusion of NGF (0.05 mg/0.5 ml each side), priming morphine (1 mg/kg) induced significant CPP, which was blocked by CeA infusion of the DOR antagonist NTD (Figure 5a ). Priming morphine was not effective on preference behavior in naive rats pre-treated with CeA infusion of saline, nor was the NGF pre-treatment alone in saline-conditioned rats. Therefore, it seems that the acute NGF in the CeA is sufficient to promote the sensitivity to opioid reward in naive rats, substituting prior opioids to induce reward sensitization.
Finally, we determined whether CeA NGF was able to reinstate morphine-induced CPP. After morphine-induced CPP was initially established and then extinct, rats in two separate groups were bilaterally infused with NGF (0.05 mg/ 0.5 ml each side) or saline into the CeA and then conditioned in the prior morphine-paired chamber. We found that the CeA NGF-conditioned rats, but not CeA saline-conditioned rats, displayed significant CPP on the first and second day after the conditioning session (Figure 5b ). The infusion site in the CeA is shown in Figure 5c .
DISCUSSION
We have shown in this study that morphing epigenetically activates the Ngf gene through histone H4 hyperacetylation Nerve growth factor and reward sensitization B Bie et al and increases NGF expression in CeA neurons, resulting in new functional DOR required for the CPP behavior and reward sensitization. In addition, both CeA-applied NGF and pharmacologically increased histone acetylation at the Ngf promoter appear to be sufficient to mimic the morphine effects in inducing functional DOR and behavior of reward sensitization. Thus, it is likely that Ngf in the CeA is one of the target genes activated epigenetically through histone modifications by opioids, and activation of this NGF signaling cascade in CeA neurons may promote behaviors of opioid reward and drug sensitization. Epigenetic mechanisms for gene regulation involve modifications of chromatin structures in core histone proteins and associated DNA through phosphorylation, acetylation, methylation, and ubiquitination (Dulac, 2010; Jenuwein and Allis, 2001; MacDonald and Roskams, 2009) . Particularly, histone acetylation reduces the electrostatic interaction between histone proteins and DNA, thus relaxing chromatin structure and making DNA more accessible to transcriptional regulators for gene activation (Kouzarides, 2007; Kurdistani et al, 2004; Strahl and Allis, 2000) . An important leap in addiction research is the recent revelation of cocaine-induced epigenetic modulations of certain gene activities (Robison and Nestler, 2011) . Nearly all addiction studies concerning epigenetic mechanisms have focused on the psychomotor stimulant cocaine. The most prominently described target gene of cocaine so far is Bdnf (encoding Nerve growth factor and reward sensitization B Bie et al BDNF), which is activated by cocaine-induced histone hyperacetylation and is directly associated with addictive behaviors of cocaine (Graham et al, 2007; Schroeder et al, 2008) . However, little is known about epigenetic modulations induced by addicting opioids and their target genes. In this study, we provide several lines of evidence showing that Ngf is an important gene epigenetically regulated by opioids and its upregulation in the CeA may be directly linked to the behavior of opioid reward and sensitization.
Both neurotrophins BDNF and NGF have diverse trophic effects on structural modifications and functional plasticity of central synapses in the adult brain (Chao and Bothwell, 2002; Poo, 2001) . Recent addiction studies have revealed BDNF as a key protein that facilitates behaviors of cocaine addiction (Graham et al, 2007; Lu et al, 2004) . However, how BDNF promotes these addiction behaviors remains largely unclear. In this regard, a recent study in neurons of prefrontal cortex shows that cocaine withdrawal-induced BDNF reduces surface expression of GABA A receptors, thereby augmenting excitatory synaptic activity and contributing to locomotor hypersensitivity in cocaine withdrawal (Lu et al, 2010) . This study in amygdala neurons demonstrates reward-promoting effects of NGF in behavioral responses to initial and subsequent opioids. Thus, it seems that both BDNF and NGF have consistent roles in promoting behaviors of drug addiction through functional coordination within specific brain regions in the brain's reward system.
Previous reports of DOR roles in drug addiction are inconsistent. Systemic administration of a DOR agonist reduces cocaine self-administration in monkeys (Do Carmo et al, 2006) , whereas infusion of a DOR agonist into the nucleus accumbens reinstates cocaine-seeking behavior in rodents (Simmons and Self, 2009) . Genetic deletion of DOR decreases the conditioned rewarding effect of morphine ), but does not change mouse self-administration of morphine into the ventral tegmental area (David et al, 2008) . Using a reward model with opioidinduced new DOR function, this study shows a reward-and sensitivity-promoting effect of CeA DOR through upregulated NGF signaling, which is in line with a previous report that systemic blockade of DOR prevents prior morphine exposure-induced sensitization to morphine reward . How DOR mediates this behavioral effect through modulation of glutamate transmission is still unknown. Although glutamate synaptic activity is critical in the mechanisms of drug reward and addiction (Bie et al, 2009b; Hyman et al, 2006; Kenny et al, 2009; Zhu et al, 2007) , the DOR effect may depend on dynamic release of endogenous opioid peptides, DOR cellular locations, and state-dependent activity of glutamate synapses.
This study provides an NGF-mediated mechanism for the behavior of opioid-induced reward sensitization. However, as both NGF and histone acetylation returned to baseline levels after CPP extinction, it is likely that other long-lasting mechanisms exist that maintain a drug-sensitized state. Nevertheless, the current findings of reward sensitivitypromoting effects of NGF may offer useful information on our understanding of molecular mechanisms underlying opioid sensitization, which is essential for the development of clinical therapies in the treatment of drug addiction and relapse. 
